Pfizer's desire to buy AstraZeneca is the biggest deal that's getting the most attention in the pharma space, but they aren't the only large drugmakers hooking up.

Last week, Novartis (NYSE:NVS)and GlaxoSmithKline (NYSE:GSK) traded products, sending Novartis' vaccines to GlaxoSmithKline and Glaxo's cancer drugs to Novartis. And the duo formed a joint venture to sell the companies' over-the-counter products. Not to be left out, Eli Lilly (NYSE:LLY) picked up Novartis' animal health business.

On the deal-rumor side, Merck (NYSE:MRK) is reportedly looking for a buyer for its consumer health-care unit. Bayer and Reckitt Benckiser appear to be the top contenders for the unit that could go for roughly $13.5 billion.

In the video below, senior biotech specialist Brian Orelli and health care analyst David Williamson discuss the activity in the pharma space as well as why we get so many rumors from "people familiar with the matter" discussing potential deals with the press.

Let's hope consolidation doesn't result in cut dividends
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Brian Orelli has no position in any stocks mentioned. David Williamson owns shares of Merck, Novartis, and Pfizer. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.